Diligent Launches AI Act Toolkits to Support Organizations in Complying with New EU AI Regulation
18.9.2024 10:00:00 CEST | Business Wire | Press release
Toolkits enable customers to identify AI systems, classify associated risk, ensure compliance with the EU's AI Act obligations and uphold global ethical best practices.
Diligent, a leading GRC SaaS company, today announced the launch of its new Artificial Intelligence (AI) Act Toolkits, designed to help corporate secretaries, legal and compliance teams, chief technology officers, chief information security officers and audit teams navigate the increasing complexity of AI governance and AI regulatory compliance. The Toolkits empower businesses operating inside and outside the European Union (EU) to understand and comply with the requirements of the EU's AI Act, and to integrate a responsible and ethical approach to AI adoption that builds trust in new technologies and adheres to global standards for AI governance.
“As the AI landscape evolves, organizations are challenged to balance innovation with regulatory compliance and ethical considerations,” said Keith Fenner, Senior Vice President & General Manager, International at Diligent. “The EU's AI Act represents a significant regulatory milestone to ensure AI systems are safe, transparent, and respect fundamental rights. We’re thrilled to offer a solution that helps customers identify and map regulatory obligations, implement best practice controls, and govern AI responsibly. This ensures compliance with evolving global regulations while accelerating the adoption of AI technology and delivering value.”
There are three toolkits available within the Diligent One Platform:
- AI Discovery and Risk Classification Toolkit – This toolkit helps customers identify their AI systems and perform the required risk classification exercise. It also provides access to an extensive library of AI literacy and best practice governance resources for the board, senior management and employees to accelerate organizational readiness and elevate AI governance. The toolkit is available to all Diligent One Platform customers.
- AI Act IT Compliance Toolkit – This toolkit helps organizations understand regulatory requirements, map them against suggested controls, and document compliance. It offers suggested control mapping to the AI Act’s regulatory requirements, gap identification, a dashboard summary for control assessment, a remediation summary and notifications to key stakeholders.
- AI Act Risk Management Toolkit – This comprehensive risk management toolkit supports a complete AI governance program. It features a risk heatmap for reviewing and prioritizing risks, a dashboard summarizing AI systems by risk level, a pre-configured AI threat library, and tools for continuous monitoring to ensure policy adherence and compliance.
In a world where, according to surveys, 78% of employees bring their own AI tools to work and 86% of businesses use some form of AI without the board’s awareness, Diligent's AI Act Toolkits are designed to support compliance, governance and risk management efforts. The Toolkits help customers to identify their AI systems and models, apply a risk-based classification, understand their obligations as providers and deployers under the AI Act, build an AI governance framework and monitor ongoing compliance. This helps to ensure that AI systems are implemented responsibly and ethically, and in a manner that documents compliance efforts in accordance with customer, partner, employee and regulator expectations.
Diligent’s Toolkits provide a robust framework for assessing and managing the risks associated with AI systems, helping organizations incorporate ethical considerations into their AI development, and supporting ongoing compliance with the EU’s AI Act. As AI becomes increasingly integral to business strategy, the Toolkits reflect Diligent's dedication to supporting ethical AI practices and helping its customers stay ahead of regulatory changes.
To learn more about the AI Act Toolkits from Diligent, visit: https://www.diligent.com/lp/eu-ai-act-compliance
About Diligent
Diligent is the leading GRC SaaS company, empowering more than 1 million users and 700,000 board members and leaders to make better decisions, faster. The Diligent One Platform helps organizations connect their entire GRC practice — including governance, risk, compliance, audit and ESG — to bring clarity to complex risk, stay ahead of regulatory changes and deliver impactful insights, in one consolidated view. Learn more at diligent.com.
Follow Diligent on LinkedIn, X (Twitter) and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240918400561/en/
Contacts
Media
Media
Julia Stoyanov
Communications Director, Diligent
+1 (604) 669-4225
Jhanbury@diligent.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
Andersen Consulting udvider med TalentSmartEQ for at fremme lederskab og virksomhedstransformation9.10.2026 18:48:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for humankapital gennem en samarbejdsaftale med TalentSmartEQ, en San Diego-baseret virksomhed, der har fokus på at skabe praktiske, engagerende og handlingsorienterede læringsoplevelser med udgangspunkt i emotionel intelligens (EQ) og lederudvikling. I mere end to årtier har TalentSmartEQ arbejdet sammen med organisationer verden over med henblik på at udvikle ledelseskompetencer ved hjælp af emotionel intelligens og dermed styrke medarbejderengagement, teamwork og de samlede resultater. Virksomheden kombinerer forskningsbaserede metoder med praktiske læringsforløb, vurderinger, coaching og skræddersyede programmer, der skal omsætte opbygningen af emotionel intelligens til vedvarende ændringer i adfærden på arbejdspladsen. Som førende aktør i branchen samarbejder TalentSmartEQ med organisationer lige fra Fortune 500-virksomheder til offentlige myndigheder og privatejede virksomheder. "Organisationer stiller stadig større krav til dere
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press release
Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation and reinforcing the security architecture behind each financial guarantee Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Sta
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press release
We think Gartner recognizes Tecnotree's open, governed approach to agentic AI as operators make AI the engine of their revenue operations Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magi
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press release
Data Presented at Annual Meeting of European Association for Cardio-Thoracic Surgery (EACTS), Along with 6 Perceval Plus E-PostersEACTS Also Marks Commercial Launch of TriMemo and Memo 4D Curve, Innovative Repair Devices for Tricuspid and Mitral Valves Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom